Enliven CFO sells 10,000 shares in open market

Enliven Therapeutics’ chief financial officer, Benjamin Hohl, sold 10,000 shares of common stock in an open-market transaction on March 6, 2026, at a weighted-average price of $29.5839 per share.

Rhea-AI Filing Summary

Enliven Therapeutics’ chief financial officer, Benjamin Hohl, sold 10,000 shares of common stock in an open-market transaction on March 6, 2026, at a weighted-average price of $29.5839 per share. After this sale, he directly owned 51,000 shares. The transaction was executed in multiple trades within a price range of $29.43 to $29.7867.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Hohl Benjamin

Role CHIEF FINANCIAL OFFICER

Sold 10,000 shs ($296K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$29.5839	$296K

Holdings After Transaction: Common Stock — 51,000 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed in multiple trades at prices ranging from $29.43 to $29.7867. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Enliven Therapeutics (ELVN) report?

Enliven Therapeutics reported that CFO Benjamin Hohl sold 10,000 shares of common stock in an open-market transaction. The sale occurred on March 6, 2026, at a weighted-average price of $29.5839 per share, executed across multiple trades within a narrow price range.

At what price did the Enliven (ELVN) CFO sell his shares?

The CFO’s sale had a weighted-average price of $29.5839 per share. According to the disclosure, the transaction was executed in multiple trades, with individual prices ranging from $29.43 to $29.7867, all on March 6, 2026, in an open-market transaction.

How many Enliven Therapeutics (ELVN) shares does the CFO hold after the sale?

After selling 10,000 shares, Enliven Therapeutics’ CFO Benjamin Hohl directly holds 51,000 shares of common stock. This figure reflects his position immediately following the March 6, 2026 open-market sale reported in the Form 4 insider transaction filing.

Was the Enliven (ELVN) CFO’s stock sale a single trade or multiple trades?

The reported sale was executed in multiple trades rather than a single transaction. The filing notes that trades occurred at prices between $29.43 and $29.7867, with the weighted-average sale price disclosed as $29.5839 per share for the 10,000 shares sold.

What type of security did the Enliven (ELVN) insider transaction involve?

The insider transaction involved Enliven Therapeutics’ common stock. CFO Benjamin Hohl sold 10,000 shares of this common stock in an open-market transaction, and the filing also notes that certain securities held are restricted stock units that convert into common shares upon vesting.

Does the Enliven (ELVN) filing mention restricted stock units (RSUs)?

Yes. The filing states that certain securities held are restricted stock units, or RSUs. Each RSU represents a contingent right to receive one share of Enliven’s common stock, subject to the specific vesting schedules and conditions that apply to each individual RSU grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 06:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hohl Benjamin

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S		10,000	D	$29.5839(1)	51,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $29.43 to $29.7867. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Benjamin Hohl	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.